Foghorn Therapeutics To Present New Preclinical Data At 2024 AACR Annual Meeting, Reflecting Advances With Multiple Potential First-In-Class Medicines, including The Selective Inhibitor Of BRM, FHD-909
Portfolio Pulse from Benzinga Newsdesk
Foghorn Therapeutics Inc. (FHTX) announced its participation in the 2024 AACR Annual Meeting with presentations on its pipeline programs, including preclinical data for FHD-909, a potential first-in-class BRM selective inhibitor. The company will present data on the efficacy and safety of FHD-909 and other programs such as selective CBP and EP300 degraders, showcasing significant anti-tumor activity and long-acting degrader capabilities for up to once-a-month dosing. IND filing for FHD-909 is planned in Q2 2024.
March 05, 2024 | 9:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Foghorn Therapeutics Inc. is set to present significant preclinical data on FHD-909 and other programs at the 2024 AACR Annual Meeting, indicating progress in developing potential first-in-class medicines.
The announcement of presenting new preclinical data at a prestigious conference and the planned IND filing for FHD-909 in Q2 2024 highlight significant progress in Foghorn Therapeutics' pipeline. This news is likely to be viewed positively by investors, as it demonstrates advancement in the development of potential first-in-class medicines, potentially leading to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100